# Santero Therapeutics SRL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/santero-therapeutics

- Industry: Biotechnology
- Headquarters: Charleroi, Belgium
- Website: www.santero.be
- Total disclosed funding: $8.7M
- Latest round: Series A (May 31, 2023)
- Investors on record: 4

## About

Founded in 2021 by Abel Garcia-Pino and Cédric Govaerts, a spin-off company of the Université libre de Bruxelles, and based in Belgium, Santero Therapeutics SRL is a biotech company that develops antibiotics against multi-drug resistant infections. In June 2023, Santero Therapeutics SRL raised EUR 8 million in Series A funding led by investor Newton Biocapital Partners, with participation from Belgium Federal Holding Company, Sambrinvest, and investor Wallonie Entreprendre. 



The company is involved in the research and development of antibiotics and other prescription drugs useful in treating multi-resistant bacteria to help improve the survival and recovery of patients during and after major surgeries and other infections. The firm targets Gram-negative bacteria that cause the majority of AMR infections.



The company intends to use the June 2023 funding to develop its antibiotics for the treatment of multi-drug-resistant infections and support its research and development initiatives for global health concerns.

## Funding rounds

- Series A, May 31, 2023, $8.7M — Belgium Federal Holding Company, Sambrinvest, Newton Biocapital Partners, Wallonie Entreprendre

## Investors

- Belgium Federal Holding Company — Series A
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Series A
- Newton Biocapital Partners (https://capitalatlas.ai/funds/newton-biocapital-partners) — Series A
- Wallonie Entreprendre — Series A